Last reviewed · How we verify
Imatinib mesylate and panitumumab
Imatinib mesylate and panitumumab is a Small molecule drug developed by Inova Health Care Services. It is currently in Phase 1 development. Also known as: Gleevec, ST1571.
At a glance
| Generic name | Imatinib mesylate and panitumumab |
|---|---|
| Also known as | Gleevec, ST1571 |
| Sponsor | Inova Health Care Services |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- New Individualized Therapy Trial for Metastatic Colorectal Cancer (PHASE1, PHASE2)
- N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imatinib mesylate and panitumumab CI brief — competitive landscape report
- Imatinib mesylate and panitumumab updates RSS · CI watch RSS
- Inova Health Care Services portfolio CI
Frequently asked questions about Imatinib mesylate and panitumumab
What is Imatinib mesylate and panitumumab?
Imatinib mesylate and panitumumab is a Small molecule drug developed by Inova Health Care Services.
Who makes Imatinib mesylate and panitumumab?
Imatinib mesylate and panitumumab is developed by Inova Health Care Services (see full Inova Health Care Services pipeline at /company/inova-health-care-services).
Is Imatinib mesylate and panitumumab also known as anything else?
Imatinib mesylate and panitumumab is also known as Gleevec, ST1571.
What development phase is Imatinib mesylate and panitumumab in?
Imatinib mesylate and panitumumab is in Phase 1.
Related
- Manufacturer: Inova Health Care Services — full pipeline
- Also known as: Gleevec, ST1571
- Compare: Imatinib mesylate and panitumumab vs similar drugs
- Pricing: Imatinib mesylate and panitumumab cost, discount & access